Literature DB >> 2939730

Effects of atrial natriuretic peptide on renin secretion in nonfiltering kidney.

T J Opgenorth, J C Burnett, J P Granger, T A Scriven.   

Abstract

Studies were performed in normal dogs (n = 6) and dogs with nonfiltering kidneys (n = 8) to determine the effects of synthetic atrial natriuretic peptide (ANP) on renin secretion and renal hemodynamics in the presence and absence of a functional macula densa. In normal dogs, intrarenal infusion of ANP (0.3 microgram X kg-1 X min-1) resulted in a decrease in renin secretion from 325.5 +/- 87.4 to 52.4 +/- 29.4 ng/ml, despite a sustained decrease in arterial pressure. In contrast, in the nonfiltering kidney without a functional macula densa, ANP infusion did not inhibit renin secretion in this nonfiltering model. Adenosine, however, known to directly inhibit renin secretion, did decrease renin secretion in this nonfiltering model. The present studies document that, in the nonfiltering kidney, ANP has no inhibitory effect on renin secretion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939730     DOI: 10.1152/ajprenal.1986.250.5.F798

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

1.  Preeminent role of the cardiorenal axis in the antihypertensive response to an arteriovenous fistula: an in silico analysis.

Authors:  John S Clemmer; W Andrew Pruett; Robert L Hester; Thomas E Lohmeier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-30       Impact factor: 4.733

2.  Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury.

Authors:  Yoshihisa Ogawa; Masashi Mukoyama; Hideki Yokoi; Masato Kasahara; Kiyoshi Mori; Yukiko Kato; Takashige Kuwabara; Hirotaka Imamaki; Tomoko Kawanishi; Kenichi Koga; Akira Ishii; Takeshi Tokudome; Ichiro Kishimoto; Akira Sugawara; Kazuwa Nakao
Journal:  J Am Soc Nephrol       Date:  2012-05-31       Impact factor: 10.121

3.  Biological actions of atrial natriuretic factor in flatfish.

Authors:  D Arnold-Reed; N Hazon; R J Balment
Journal:  Fish Physiol Biochem       Date:  1991-06       Impact factor: 2.794

Review 4.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

5.  Regulation of prorenin secretion in cultured human transfected juxtaglomerular cells.

Authors:  F Pinet; J Mizrahi; I Laboulandine; J Menard; P Corvol
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

6.  Role of the heart in blood pressure lowering during chronic baroreflex activation: insight from an in silico analysis.

Authors:  John S Clemmer; W Andrew Pruett; Robert L Hester; Radu Iliescu; Thomas E Lohmeier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-13       Impact factor: 4.733

7.  A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction.

Authors:  T L Stevens; J C Burnett; M Kinoshita; Y Matsuda; M M Redfield
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

Review 8.  Atrial natriuretic factor: physiologic actions and implications in congestive heart failure.

Authors:  B S Edwards; R S Zimmerman; J C Burnett
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

Review 9.  Atrial Natriuretic Peptide: Structure, Function, and Physiological Effects: A Narrative Review.

Authors:  Sanjana Rao; Camilo Pena; Scott Shurmur; Kenneth Nugent
Journal:  Curr Cardiol Rev       Date:  2021

10.  In silico trial of baroreflex activation therapy for the treatment of obesity-induced hypertension.

Authors:  John S Clemmer; W Andrew Pruett; Robert L Hester
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.